Ardelyx, Inc.
- ARDX
- NASDAQ
- Biotechnology
- Gastrointestinal (GI) Drugs
- Cardiorenal Treatments
$3.13
Today +1.46%Quote Oct 20, 2026, 02:09 PM UTC
−9.65%over the last month
Max drawdown −14.6%From 1-month high −14.6%3 months −39.3%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Ardelyx
Ardelyx, Inc. is a biopharmaceutical firm dedicated to the discovery, development, and commercialization of innovative medicines. The company primarily focuses on addressing gastrointestinal (GI) and cardiorenal conditions, serving patients both domestically in the United States and across international markets.
Where the money comes from
Q2 2026 revenue $204.5M
- Product$118.1M57.8%
- Product, IBSRELA$86.2M42.2%
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
489
Founded
2007
Market value
$781.2M
Quote Oct 20
Analyst target
$13.00
+314.7% from here
Floor
$2.98
4.8% below price
Resistance
$3.17
1.0% above price
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about ARDXPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free